Colorectal Carcinoma/CD3 antibody

Catalog No. ABIN452572

Product Details

Target: Colorectal Carcinoma/CD3

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Enzyme Immunoassay (EIA), Flow Cytometry (FACS)

Cross-Reactivity (Details): Species reactivity (tested):Human.

Characteristics: Synonyms: CRC/CD3, Hybrid bispecific antibody

Purification: Affinity Chromatography on Protein G.

Clone: BS-1

Isotype: IgG1/IgG2a

Application Details

Application Notes: ELISA.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Reconstitution: Restore with Double distillated water to adjust the final concentration to 1.0 mg/mL.

Buffer: 0.01 M PBS, pH 7.0 without preservatives

Preservative: Without preservative

Storage: -20 °C

Storage Comment: Store the antibody at -20 °C. After reconstitution, aliquot and store at -20 °C.
Shelf life: one year from despatch.

Expiry Date: 12 months

Target Details

Target: Colorectal Carcinoma/CD3

Background: Colorectal carcinoma is the cancer developed in the colon or rectum of the digestive system. In developed countries, it is the most common cancer in aging population. Genetic deposition and a less active life style contribute to the development of the cancer. Molecular pathological study showed that altered Wnt-APC-β-catenim signaling pathway, mutated p53, and deactivated TGF-β and DCC (Deleted in Colon Cancer) are involved with the pathogenesis. The cancer is currently screened with a fecal occult blood test in people over 50 years old and the malignancy is confirmed by tumor biopsy. The search for specific biomarker for non-invasive test is still ongoing. CD3 exists on the cell surface of all T-cell types. It is used for differentiating Tcells from other leukocytes such as B cells and natural killer cells. CD3 is the accessory molecule in the T cell receptorcomplex. In the presence of CD3 and ζ- chain, T-cell receptor binds to antigen presented by MHC and transfers signal for T-cell activation. The hybrid bi-specific antibody binds to CD3 and colorectal carcinoma related antigen at its two different Fabs. Theoretically, the bi-specific antibody brings the target cancer antigen near Tcells and could enhance T-cell mediated immunity to cancer. However, if the binding to CD3 disrupts the CD3's accessory function, T-cell immunity suppression could be resulted.Synonyms: CRC/CD3, Hybrid bispecific antibody